Panagiotis Konstantinopoulos
, Director of Translational Research, Gynecologic Oncology, and · Mass General Brigham
Credentials: · · · ·
History
- Present
Mellen and Eisenson Family Center for BRCA and Related Genes · Mass General Brigham
- 2000–2002
- 1997–2000
State University of New York University Hospital
- 1993–1997
Research
Replication fork stability confers chemoresistance in BRCA-deficient cells
Nature · 2016 · 784 citations
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Nature · 2015 · 766 citations
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Review · Cancer Discovery · 2015 · First of 4 authors · Corresponding · 764 citations
77 papers
47 papers
26 papers
20 papers
18 papers · 2 as a fellow
18 papers
16 papers
16 papers
Grants
- 2024–2029
Targeting Replication Stress and DNA Damage Response in Uterine Cancer
National Cancer Institute · P01
PI · $8.9M · Dana-Farber Cancer Inst
- 2022–2027
Targeting CDK7 in CCNE1-Amplified Ovarian Cancer
National Cancer Institute · R01
PI · $3.5M · Stanford University
- 2020–2025
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE Grant
National Cancer Institute · P50
Project lead · $1.8M · Dana-Farber Cancer Inst
Clinical trials
- 2026–2029
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
Principal investigator · Not yet recruiting · Phase 2
Dana-Farber Cancer Institute
- 2024–2029
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Principal investigator · Recruiting · Phase 2
Dana-Farber Cancer Institute
- 2024–2029
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Principal investigator · Recruiting · Phase 2
Panagiotis Konstantinopoulos, MD, PhD
- 2024–2029
ALPINE: Maintenance Letrozole/Abemaciclib
Principal investigator · Recruiting · Phase 2
Dana-Farber Cancer Institute